Compare ANAB & GILT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANAB | GILT |
|---|---|---|
| Founded | 2005 | 1987 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 843.0M |
| IPO Year | 2015 | 1997 |
| Metric | ANAB | GILT |
|---|---|---|
| Price | $53.61 | $11.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 2 |
| Target Price | ★ $71.67 | $19.00 |
| AVG Volume (30 Days) | ★ 818.3K | 553.3K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $234,603,000.00 | N/A |
| Revenue This Year | N/A | $15.06 |
| Revenue Next Year | $52.14 | $11.72 |
| P/E Ratio | ★ N/A | $42.82 |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $17.11 | $7.22 |
| 52 Week High | $73.30 | $20.99 |
| Indicator | ANAB | GILT |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 37.62 |
| Support Level | $52.32 | $10.42 |
| Resistance Level | $57.70 | $13.82 |
| Average True Range (ATR) | 4.55 | 0.55 |
| MACD | -0.98 | 0.04 |
| Stochastic Oscillator | 24.72 | 18.58 |
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company operates in three operating segments: Gilat Commercial Division, Gilat Defense Division, and Gilat Peru Division. The majority of its revenue is generated from the Gilat Commercial segment.